References of "Witvrouw, Nancy"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux en hématologie en 2009
Bonnet, Christophe ULg; Beguin, Yves ULg; De Prijck, Bernard ULg et al

in Revue Médicale de Liège (2009), 64

Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's lymphoma and ... [more ▼]

Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's lymphoma and offers superior response and survival rates. 90Y ibritumomab tiuxetan (Zevalin) combines the specificity of rituximab for the CD20 antigen and the therapeutic effect of β irradiation. Given in monotherapy, it constitutes an interesting alternative therapy for follicular lymphomas in second relapse. Alemtuzumab (MabCampath) recognizes the CD52 antigen and offers encouraging results in chronic lymphocytic leukemia resistant to classical chemotherapy. [less ▲]

Detailed reference viewed: 193 (14 ULg)
Full Text
Peer Reviewed
See detailLiver metastases
Hustinx, Roland ULg; Witvrouw, Nancy ULg; Tancredi, Tino ULg

in PET Clinics (2008), 3

Detailed reference viewed: 26 (3 ULg)
Full Text
Peer Reviewed
See detailIndications cliniques de la radiotherapie metabolique dans les lymphomes
Witvrouw, Nancy ULg; De Prijck, Bernard ULg; Hustinx, Roland ULg

in Revue Médicale Suisse (2008), 4(168), 1818-22

In their later stages low grade lymphoma are incurable. These lymphomas being radio-sensitive, a treatment of metabolic radioimmunotherapy, using monoclonal antibodies (anti-CD20) as the carrier has been ... [more ▼]

In their later stages low grade lymphoma are incurable. These lymphomas being radio-sensitive, a treatment of metabolic radioimmunotherapy, using monoclonal antibodies (anti-CD20) as the carrier has been developed. The aim of this treatment is to use these antibodies to target radiation to tumor tissues while limiting toxicity to normal cells. Ibritumomab tiuxetan (Zevalin) is currently prescribed for patients with relapsed or refractory low-grade follicular lymphoma after rituximab treatment. This outpatient treatment has a high level of overall response rate including complete response and that for a long period. The side effects are essentially hematological and reversible. In the near future many more indications should become apparent and Zevalin should become an important tool in the B-cell lymphoma (low and high grade). [less ▲]

Detailed reference viewed: 73 (4 ULg)
Full Text
Peer Reviewed
See detailBack pain and renal failure
Delanaye, Pierre ULg; Bovy, Christophe ULg; de Leval, Laurence ULg et al

in Lancet (2004), 364(9449), 1992

Detailed reference viewed: 32 (14 ULg)